Health Monthly Martinique: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monthly Martinique.

Press releases published on July 29, 2026

Jul. 29, 2026

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies 

Indeterminate GlobeNewswire

Jul. 29, 2026

TRUE-See Systems Announces New Venture Funding

Indeterminate GlobeNewswire

Jul. 29, 2026

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

Indeterminate GlobeNewswire

Jul. 29, 2026

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

Indeterminate GlobeNewswire

Jul. 29, 2026

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Indeterminate GlobeNewswire

Jul. 29, 2026

Fortrea Reports Second Quarter 2026 Results

Indeterminate GlobeNewswire

Jul. 29, 2026

Shape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s Disease

Indeterminate GlobeNewswire

Jul. 29, 2026

Integra LifeSciences Reports Second Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Jul. 29, 2026

Tasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155)

Indeterminate GlobeNewswire

Jul. 29, 2026

Alira Health Establishes Annabel de Maria Memorial Scholarship to Inspire the Next Generation of Healthcare Leaders

Indeterminate GlobeNewswire

Jul. 29, 2026

Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications

Indeterminate GlobeNewswire

Jul. 29, 2026

Shades For Migraine Awareness Campaign Sees Record Growth as Global Community Expands

Indeterminate GlobeNewswire

Jul. 29, 2026

Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 30 Mio. für die Phase-3-Entwicklung des neuen Antipilzmittels Fosmanogepix

Indeterminate GlobeNewswire

Jul. 29, 2026

Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix

Indeterminate GlobeNewswire